United States

Business

ESMO: Bristol Myers preps 2nd kidney cancer combo nod as Opdivo-Cabometyx duo slashes death risk 40% - FiercePharma

  1. ESMO: Bristol Myers preps 2nd kidney cancer combo nod as Opdivo-Cabometyx duo slashes death risk 40%  FiercePharma
  2. ESMO 2020 Highlights on nivolumab+cabozantinib as 1st line therapy for aRCC: The CheckMate 9ER study  European Society for Medical Oncology
  3. Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial  Yahoo Finance
  4. First-line nivolumab-cabozantinib superior to sunitinib for advanced renal cell carcinoma  Healio
  5. New first-line treatment option for metastatic kidney cancer  Medical Xpress
  6. View Full Coverage on Google News

Published on 19 September 2020 | 4:30 pm






Friendly sites: